Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: Journal of Medical Internet Research

Date Submitted: May 1, 2020
Date Accepted: Jun 14, 2020

The final, peer-reviewed published version of this preprint can be found here:

QardioArm Blood Pressure Monitoring in a Population With Type 2 Diabetes: Validation Study

Mazoteras-Pardo V, Becerro-De-Bengoa-Vallejo R, Losa-Iglesias ME, Martínez-Jiménez EM, Calvo-Lobo C, Romero-Morales C, López-López D, Palomo-López P

QardioArm Blood Pressure Monitoring in a Population With Type 2 Diabetes: Validation Study

J Med Internet Res 2020;22(7):e19781

DOI: 10.2196/19781

PMID: 32706672

PMCID: 7414407

QardioArm® in non-insulin-dependent diabetes mellitus type II population: Validation Study

  • Victoria Mazoteras-Pardo; 
  • Ricardo Becerro-De-Bengoa-Vallejo; 
  • Marta Elena Losa-Iglesias; 
  • Eva María Martínez-Jiménez; 
  • César Calvo-Lobo; 
  • Carlos Romero-Morales; 
  • Daniel López-López; 
  • Patricia Palomo-López

ABSTRACT

Background:

Home blood pressure monitoring has many benefits, and even more so, in populations prone to high blood pressure, such as diabetics.

Objective:

The purpose of this research was to find out the validity of a QardioArm mobile device in non-insulin-dependent type 2 diabetic population following the guidelines in accordance with the second International Protocol of the European Society of Hypertension (ESH-IP2).

Methods:

The sample examined were 33 subjects with type 2 diabetes mellitus. Two nurses evaluated the validity of QardioArm by comparing their data with that obtained with digital sphygmomanometer (Omron M3 Intellisense). They measured with the two devices the three main variables: diatolic and systolic blood pressure and heart rate.

Results:

The analysis indicated that the test device QardioArm met all the validation requirements in population with type 2 diabetes.

Conclusions:

This paper is the first validation of QardioArm in non-insulin-dependent type 2 diabetic population.


 Citation

Please cite as:

Mazoteras-Pardo V, Becerro-De-Bengoa-Vallejo R, Losa-Iglesias ME, Martínez-Jiménez EM, Calvo-Lobo C, Romero-Morales C, López-López D, Palomo-López P

QardioArm Blood Pressure Monitoring in a Population With Type 2 Diabetes: Validation Study

J Med Internet Res 2020;22(7):e19781

DOI: 10.2196/19781

PMID: 32706672

PMCID: 7414407

Per the author's request the PDF is not available.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.